Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Since the first discovery of EGFR-tyrosine kinase inhibitors (TKIs), they have become the gold standard treatment for EGFR-mutated non-small cell lung cancer. However, the inevitable acquisition of secondary TKI resistance after treatment with TKIs remains an unresolved issue. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeo, Min-Kyung, Kim, Yoonjoo, Lee, Da Hye, Chung, Chaeuk, Bae, Go Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221089/
https://www.ncbi.nlm.nih.gov/pubmed/35740609
http://dx.doi.org/10.3390/cancers14122940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221089/
https://www.ncbi.nlm.nih.gov/pubmed/35740609
http://dx.doi.org/10.3390/cancers14122940

Ejemplares similares